Brookfield Asset Management - CEREVEL THERAPEUTICS HLDNG I ownership

CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 59 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.9%.

Quarter-by-quarter ownership
Brookfield Asset Management ownership history of CEREVEL THERAPEUTICS HLDNG I
ValueSharesWeighting
Q3 2021$1,275,000
+68.7%
43,204
+46.4%
0.01%
+25.0%
Q2 2021$756,000
+127.0%
29,514
+21.7%
0.00%
+100.0%
Q1 2021$333,000
-44.8%
24,253
-33.3%
0.00%
-33.3%
Q4 2020$603,00036,3550.00%
Other shareholders
CEREVEL THERAPEUTICS HLDNG I shareholders Q4 2020
NameSharesValueWeighting ↓
BAIN CAPITAL INVESTORS LLC 60,199,729$1,913,749,38528.70%
Perceptive Advisors 10,088,385$320,709,7599.28%
Affinity Asset Advisors, LLC 550,000$17,484,5006.11%
Finepoint Capital LP 492,545$15,658,0065.42%
Paradigm Biocapital Advisors LP 1,868,946$59,413,7934.59%
BOONE CAPITAL MANAGEMENT LLC 300,000$9,537,0003.42%
Rock Springs Capital Management LP 2,513,916$79,917,3901.90%
Artal Group S.A. 1,638,858$52,0991.62%
Frazier Life Sciences Management, L.P. 393,000$12,493,4700.75%
Avidity Partners Management LP 501,200$15,933,1480.56%
View complete list of CEREVEL THERAPEUTICS HLDNG I shareholders